ANDA 40404, held by Able Laboratories. Methylphenidate Hydrochloride.
As of Nov 19, 2026, ANDA 40404 (Methylphenidate Hydrochloride), held by Able Laboratories, was first approved by FDA on Mar 29, 2001, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 29, 2001 | Original application | Approved |
| Methylphenidate Hydrochloride5MG · tablet;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride10MG · tablet;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride20MG · tablet;oral | Methylphenidate Hydrochloride | Discontinued |
| May 9, 2003 | Supplement 3Labeling | Approved | None posted |
| Mar 5, 2003 | Supplement 2Labeling | Approved | None posted |
| May 25, 2001 | Supplement 1Manufacturing | Approved | None posted |
| Mar 29, 2001 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters